NH SB504 authorizes licensed healthcare professionals to dispense up to a 30-day supply of noncontrolled oral anti-cancer medications under provider supervision, expands remote processing capabilities for advanced pharmacy technicians, removes the requirement for pharmacist identification on controlled drug labels, broadens the definition of pharmacy practice, and eliminates examination requirements and pharmacy law testing for advanced pharmacy technician licensure. The bill also reduces the pharmacy board's regulatory authority over collaborative pharmacy practice agreements and changes license display requirements from conspicuous posting to readily retrievable format. These changes collectively shift regulatory focus away from restrictive oversight toward expanded clinical flexibility and professional autonomy.

Why It Matters to MAHA

MAHA strongly supports this bill because it removes unnecessary regulatory barriers that restrict patient access to medications and healthcare services. By allowing qualified healthcare professionals to dispense anti-cancer medications and enabling pharmacists to practice at the full scope of their training without redundant bureaucratic oversight, the bill expands treatment access and patient choice. Eliminating mandatory pharmacy law examinations and reducing board authority over practice agreements removes government gatekeeping that does not improve patient safety but instead limits innovation in medication delivery and collaborative care models. The expansion of remote processing capabilities increases convenience and accessibility for patients while trusting qualified professionals to deliver safe care. This legislation exemplifies health freedom by prioritizing patient autonomy and professional expertise over rigid regulatory control.